Acquired hypothalamic obesity as α-MSH deficiency syndrome: a paradigm shift with therapeutic impact

Description

Martin Wabitsch, Kim Ulrich, and Christian Denzer argue for a new way of seeing obesity caused by hypothalamus damage, in a 2026 paper. This condition follows brain tumors or their treatment and brings rapid, stubborn weight gain, constant hunger, and low energy burn. Mechanism-based treatments have been missing for decades.

Recent trial evidence suggests the problem is really a hormone shortage. The damaged hypothalamus underproduces a signaling peptide that normally tells the brain to curb appetite. Downstream circuits still work, shown by the strong response to a drug that activates the same receptor the missing hormone targets. The authors frame the drug as hormone replacement, like insulin for diabetes. The reframing, they argue, should change diagnosis and management, moving care from generic weight advice toward replacing the lost signal.

Catalog record

Source: https://europepmc.org/articles/PMC13672725